| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms, Castration-Resistant | 35 | 2024 | 110 | 8.440 |
Why?
|
| Phenylthiohydantoin | 21 | 2025 | 48 | 3.580 |
Why?
|
| Prostatic Neoplasms | 31 | 2025 | 1769 | 3.190 |
Why?
|
| Benzamides | 21 | 2025 | 246 | 3.100 |
Why?
|
| Nitriles | 21 | 2025 | 154 | 2.750 |
Why?
|
| Androstenes | 13 | 2024 | 38 | 2.650 |
Why?
|
| Receptors, Glucocorticoid | 7 | 2024 | 144 | 2.280 |
Why?
|
| Receptors, Androgen | 14 | 2024 | 120 | 1.930 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 12 | 2024 | 2543 | 1.330 |
Why?
|
| Androgen Antagonists | 14 | 2025 | 143 | 1.290 |
Why?
|
| Neoplasm Metastasis | 21 | 2024 | 1060 | 1.190 |
Why?
|
| Neoplastic Cells, Circulating | 6 | 2024 | 72 | 1.160 |
Why?
|
| Antineoplastic Agents | 11 | 2023 | 2301 | 1.080 |
Why?
|
| Androgen Receptor Antagonists | 6 | 2024 | 20 | 0.890 |
Why?
|
| Male | 67 | 2025 | 44355 | 0.830 |
Why?
|
| Food-Drug Interactions | 2 | 2014 | 19 | 0.790 |
Why?
|
| Sulfonamides | 5 | 2019 | 331 | 0.780 |
Why?
|
| Prostate-Specific Antigen | 8 | 2025 | 337 | 0.700 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2018 | 603 | 0.700 |
Why?
|
| Aged, 80 and over | 27 | 2025 | 7039 | 0.680 |
Why?
|
| Testosterone | 4 | 2021 | 258 | 0.620 |
Why?
|
| Humans | 74 | 2025 | 93132 | 0.600 |
Why?
|
| Aged | 39 | 2025 | 20395 | 0.590 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2019 | 223 | 0.580 |
Why?
|
| Orchiectomy | 4 | 2018 | 63 | 0.580 |
Why?
|
| Quality of Life | 6 | 2024 | 1776 | 0.580 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2024 | 376 | 0.570 |
Why?
|
| Pyrimidines | 5 | 2019 | 382 | 0.540 |
Why?
|
| Ascites | 1 | 2018 | 53 | 0.540 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2022 | 1339 | 0.520 |
Why?
|
| Food | 1 | 2018 | 92 | 0.520 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2023 | 302 | 0.510 |
Why?
|
| Prospective Studies | 12 | 2024 | 4546 | 0.510 |
Why?
|
| Small Molecule Libraries | 1 | 2017 | 69 | 0.490 |
Why?
|
| Middle Aged | 34 | 2025 | 27535 | 0.490 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 188 | 0.490 |
Why?
|
| Cell Line, Tumor | 10 | 2024 | 2757 | 0.470 |
Why?
|
| SOXB1 Transcription Factors | 3 | 2023 | 23 | 0.470 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2016 | 636 | 0.420 |
Why?
|
| Disease Progression | 7 | 2020 | 1529 | 0.420 |
Why?
|
| Prednisone | 4 | 2022 | 242 | 0.420 |
Why?
|
| Patient Safety | 4 | 2019 | 219 | 0.410 |
Why?
|
| Immediate-Early Proteins | 2 | 2014 | 161 | 0.400 |
Why?
|
| Carcinoma, Small Cell | 1 | 2014 | 115 | 0.400 |
Why?
|
| MAP Kinase Kinase 4 | 2 | 2011 | 60 | 0.400 |
Why?
|
| Treatment Outcome | 18 | 2024 | 9070 | 0.390 |
Why?
|
| Dietary Fats | 1 | 2014 | 134 | 0.390 |
Why?
|
| Food Labeling | 1 | 2012 | 7 | 0.380 |
Why?
|
| Indoles | 1 | 2014 | 298 | 0.360 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 1000 | 0.360 |
Why?
|
| Neoplasms | 6 | 2023 | 3168 | 0.350 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 2024 | 100 | 0.350 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2011 | 68 | 0.330 |
Why?
|
| Melanoma | 1 | 2014 | 494 | 0.300 |
Why?
|
| Signal Transduction | 9 | 2024 | 3497 | 0.300 |
Why?
|
| Mice, Nude | 4 | 2017 | 823 | 0.300 |
Why?
|
| Cell Survival | 3 | 2017 | 1002 | 0.290 |
Why?
|
| Mifepristone | 2 | 2022 | 50 | 0.280 |
Why?
|
| Hormones | 3 | 2022 | 136 | 0.260 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2024 | 87 | 0.250 |
Why?
|
| Biomarkers, Tumor | 6 | 2024 | 1660 | 0.240 |
Why?
|
| Breast Neoplasms | 2 | 2021 | 3155 | 0.230 |
Why?
|
| Homeodomain Proteins | 3 | 2024 | 556 | 0.230 |
Why?
|
| Androgens | 3 | 2023 | 163 | 0.220 |
Why?
|
| Neutropenia | 2 | 2023 | 209 | 0.210 |
Why?
|
| Phthalazines | 1 | 2024 | 53 | 0.210 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2024 | 12 | 0.210 |
Why?
|
| Nuclear Medicine | 1 | 2023 | 12 | 0.200 |
Why?
|
| Adenocarcinoma | 2 | 2020 | 1171 | 0.190 |
Why?
|
| CDC2 Protein Kinase | 1 | 2023 | 46 | 0.190 |
Why?
|
| Radium | 1 | 2023 | 7 | 0.190 |
Why?
|
| Piperazines | 1 | 2024 | 284 | 0.190 |
Why?
|
| Kidney Neoplasms | 2 | 2019 | 531 | 0.190 |
Why?
|
| Capecitabine | 2 | 2024 | 97 | 0.190 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2023 | 123 | 0.190 |
Why?
|
| Disease-Free Survival | 4 | 2023 | 1171 | 0.180 |
Why?
|
| Dehydroepiandrosterone | 2 | 2020 | 45 | 0.180 |
Why?
|
| Neoplasms, Second Primary | 1 | 2024 | 244 | 0.180 |
Why?
|
| Urinary Bladder | 1 | 2024 | 257 | 0.180 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2024 | 151 | 0.170 |
Why?
|
| Frailty | 1 | 2023 | 94 | 0.170 |
Why?
|
| Cell Proliferation | 4 | 2017 | 1732 | 0.170 |
Why?
|
| Abiraterone Acetate | 2 | 2018 | 11 | 0.170 |
Why?
|
| Chromosomal Instability | 1 | 2021 | 22 | 0.170 |
Why?
|
| Castration | 2 | 2012 | 32 | 0.170 |
Why?
|
| Cell Cycle Proteins | 1 | 2023 | 409 | 0.160 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2020 | 16 | 0.160 |
Why?
|
| Health Expenditures | 1 | 2021 | 98 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2019 | 1908 | 0.160 |
Why?
|
| Glucocorticoids | 2 | 2024 | 360 | 0.160 |
Why?
|
| DNA Methylation | 1 | 2025 | 699 | 0.160 |
Why?
|
| Dietary Supplements | 1 | 2021 | 130 | 0.160 |
Why?
|
| Double-Blind Method | 5 | 2025 | 1727 | 0.150 |
Why?
|
| Organic Chemicals | 1 | 2019 | 36 | 0.150 |
Why?
|
| Animals | 8 | 2024 | 27973 | 0.150 |
Why?
|
| Pain | 1 | 2022 | 412 | 0.150 |
Why?
|
| Boronic Acids | 1 | 2019 | 55 | 0.150 |
Why?
|
| Oxidoreductases | 1 | 2019 | 111 | 0.150 |
Why?
|
| Taxoids | 2 | 2016 | 126 | 0.150 |
Why?
|
| Pyridones | 1 | 2019 | 66 | 0.140 |
Why?
|
| United States | 6 | 2020 | 7581 | 0.140 |
Why?
|
| Aurora Kinase A | 1 | 2018 | 15 | 0.140 |
Why?
|
| Azepines | 1 | 2018 | 28 | 0.140 |
Why?
|
| Pyrrolidinones | 1 | 2018 | 15 | 0.140 |
Why?
|
| Immunoconjugates | 1 | 2019 | 129 | 0.140 |
Why?
|
| N-Myc Proto-Oncogene Protein | 1 | 2018 | 40 | 0.140 |
Why?
|
| Myeloid Ecotropic Viral Integration Site 1 Protein | 1 | 2018 | 20 | 0.140 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2018 | 40 | 0.140 |
Why?
|
| Recurrence | 2 | 2019 | 1188 | 0.140 |
Why?
|
| Singapore | 1 | 2018 | 14 | 0.140 |
Why?
|
| Bone Neoplasms | 1 | 2020 | 308 | 0.140 |
Why?
|
| Quinolines | 1 | 2018 | 85 | 0.130 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 279 | 0.130 |
Why?
|
| Adult | 13 | 2021 | 27849 | 0.130 |
Why?
|
| Urologic Neoplasms | 1 | 2018 | 78 | 0.130 |
Why?
|
| Fasting | 1 | 2018 | 164 | 0.130 |
Why?
|
| Mice | 6 | 2024 | 12230 | 0.130 |
Why?
|
| Enzyme Inhibitors | 1 | 2020 | 638 | 0.130 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 103 | 0.130 |
Why?
|
| Feasibility Studies | 2 | 2021 | 753 | 0.130 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2018 | 244 | 0.130 |
Why?
|
| Prostatectomy | 1 | 2020 | 472 | 0.130 |
Why?
|
| Neoadjuvant Therapy | 1 | 2020 | 446 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2018 | 199 | 0.120 |
Why?
|
| Combined Modality Therapy | 4 | 2024 | 1719 | 0.120 |
Why?
|
| Quinolones | 1 | 2016 | 57 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2016 | 526 | 0.120 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 327 | 0.120 |
Why?
|
| Tissue Array Analysis | 2 | 2018 | 134 | 0.120 |
Why?
|
| Benzodioxoles | 1 | 2015 | 15 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 885 | 0.110 |
Why?
|
| Female | 10 | 2021 | 48542 | 0.110 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2019 | 357 | 0.110 |
Why?
|
| Steroid Synthesis Inhibitors | 1 | 2014 | 1 | 0.110 |
Why?
|
| Maximum Tolerated Dose | 3 | 2019 | 258 | 0.110 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2016 | 278 | 0.110 |
Why?
|
| Quinazolines | 1 | 2015 | 211 | 0.110 |
Why?
|
| Metribolone | 1 | 2014 | 5 | 0.100 |
Why?
|
| Estrogen Receptor alpha | 1 | 2015 | 155 | 0.100 |
Why?
|
| Proteins | 1 | 2019 | 790 | 0.100 |
Why?
|
| Benzoates | 1 | 2014 | 33 | 0.100 |
Why?
|
| Prognosis | 3 | 2018 | 3890 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2018 | 660 | 0.100 |
Why?
|
| Life Expectancy | 1 | 2014 | 90 | 0.100 |
Why?
|
| Immunoblotting | 1 | 2014 | 273 | 0.100 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2014 | 98 | 0.100 |
Why?
|
| Population Surveillance | 1 | 2014 | 212 | 0.100 |
Why?
|
| Flow Cytometry | 1 | 2014 | 710 | 0.090 |
Why?
|
| RNA Interference | 1 | 2014 | 379 | 0.090 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 396 | 0.090 |
Why?
|
| Hospitalization | 1 | 2018 | 924 | 0.090 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2014 | 289 | 0.090 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 435 | 0.090 |
Why?
|
| Transcription, Genetic | 1 | 2017 | 1114 | 0.090 |
Why?
|
| Transcription Factors | 2 | 2018 | 1687 | 0.090 |
Why?
|
| Dexamethasone | 1 | 2014 | 311 | 0.090 |
Why?
|
| Immunotherapy | 1 | 2018 | 762 | 0.090 |
Why?
|
| Indazoles | 3 | 2019 | 58 | 0.090 |
Why?
|
| HEK293 Cells | 1 | 2014 | 696 | 0.090 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2011 | 35 | 0.080 |
Why?
|
| Decision Making | 2 | 2014 | 671 | 0.080 |
Why?
|
| G1 Phase | 1 | 2011 | 64 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2014 | 1518 | 0.080 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2011 | 156 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 1447 | 0.080 |
Why?
|
| Survival Rate | 3 | 2019 | 1945 | 0.080 |
Why?
|
| Tumor Burden | 1 | 2011 | 321 | 0.080 |
Why?
|
| Chicago | 3 | 2025 | 1452 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 1703 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2013 | 443 | 0.080 |
Why?
|
| Nausea | 2 | 2019 | 93 | 0.070 |
Why?
|
| Administration, Cutaneous | 1 | 2009 | 61 | 0.070 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 504 | 0.070 |
Why?
|
| Tissue Distribution | 2 | 2019 | 287 | 0.070 |
Why?
|
| Prostate | 3 | 2018 | 416 | 0.070 |
Why?
|
| Muscle Strength | 1 | 2009 | 38 | 0.070 |
Why?
|
| Research Design | 1 | 2012 | 620 | 0.070 |
Why?
|
| Geriatric Assessment | 2 | 2023 | 187 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 1786 | 0.060 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 1980 | 0.060 |
Why?
|
| Age Factors | 2 | 2023 | 1898 | 0.060 |
Why?
|
| Rats | 1 | 2011 | 4028 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2024 | 2434 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 3450 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2024 | 3814 | 0.050 |
Why?
|
| CpG Islands | 1 | 2025 | 168 | 0.050 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2024 | 64 | 0.050 |
Why?
|
| Leuprolide | 1 | 2024 | 34 | 0.050 |
Why?
|
| Comorbidity | 2 | 2021 | 1003 | 0.050 |
Why?
|
| Precision Medicine | 2 | 2023 | 457 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 2705 | 0.050 |
Why?
|
| Scandium | 1 | 2023 | 4 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2024 | 10128 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2021 | 3044 | 0.050 |
Why?
|
| Radioisotopes | 1 | 2023 | 39 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2024 | 2020 | 0.050 |
Why?
|
| DNA, Complementary | 1 | 2024 | 379 | 0.050 |
Why?
|
| BRCA2 Protein | 1 | 2024 | 173 | 0.050 |
Why?
|
| BRCA1 Protein | 1 | 2024 | 215 | 0.050 |
Why?
|
| Cystectomy | 1 | 2024 | 113 | 0.050 |
Why?
|
| DNA Repair | 1 | 2024 | 359 | 0.050 |
Why?
|
| Early Termination of Clinical Trials | 2 | 2012 | 15 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2020 | 2009 | 0.050 |
Why?
|
| Febrile Neutropenia | 1 | 2022 | 16 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2022 | 33 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2024 | 570 | 0.040 |
Why?
|
| Aminopyridines | 1 | 2022 | 48 | 0.040 |
Why?
|
| Cisplatin | 1 | 2024 | 567 | 0.040 |
Why?
|
| Thyrotoxicosis | 1 | 2001 | 18 | 0.040 |
Why?
|
| Purines | 1 | 2022 | 91 | 0.040 |
Why?
|
| Tissue Extracts | 1 | 2021 | 24 | 0.040 |
Why?
|
| Cellular Reprogramming | 1 | 2022 | 50 | 0.040 |
Why?
|
| Time Factors | 2 | 2020 | 5380 | 0.040 |
Why?
|
| Interleukin-7 | 1 | 2021 | 47 | 0.040 |
Why?
|
| Keratins | 1 | 2021 | 62 | 0.040 |
Why?
|
| Leukocyte Common Antigens | 1 | 2021 | 50 | 0.040 |
Why?
|
| Neurosecretory Systems | 1 | 2021 | 35 | 0.040 |
Why?
|
| Glycolysis | 1 | 2022 | 186 | 0.040 |
Why?
|
| Cell Count | 1 | 2021 | 195 | 0.040 |
Why?
|
| Asymptomatic Diseases | 1 | 2021 | 44 | 0.040 |
Why?
|
| Thyroid Hormone Resistance Syndrome | 1 | 2001 | 117 | 0.040 |
Why?
|
| Prescription Drugs | 1 | 2021 | 38 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2021 | 237 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2025 | 555 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2021 | 389 | 0.040 |
Why?
|
| RNA | 1 | 2024 | 574 | 0.040 |
Why?
|
| Neutrophils | 1 | 2021 | 324 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 981 | 0.040 |
Why?
|
| Steroids | 1 | 2020 | 166 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2021 | 453 | 0.040 |
Why?
|
| Vomiting | 1 | 2019 | 108 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2013 | 298 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 290 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 512 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2011 | 2363 | 0.040 |
Why?
|
| Pregnancy Complications | 1 | 2001 | 350 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2021 | 798 | 0.030 |
Why?
|
| Bradycardia | 1 | 2018 | 46 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2019 | 295 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 827 | 0.030 |
Why?
|
| Mitochondria | 1 | 2022 | 612 | 0.030 |
Why?
|
| Kinetics | 1 | 2020 | 1463 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 2019 | 356 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 874 | 0.030 |
Why?
|
| Risk Factors | 2 | 2020 | 5900 | 0.030 |
Why?
|
| Prevalence | 1 | 2021 | 1318 | 0.030 |
Why?
|
| Remission Induction | 1 | 2018 | 737 | 0.030 |
Why?
|
| Transcriptome | 1 | 2021 | 762 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 655 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 537 | 0.030 |
Why?
|
| Nanog Homeobox Protein | 1 | 2014 | 8 | 0.030 |
Why?
|
| Ketoconazole | 1 | 2014 | 23 | 0.030 |
Why?
|
| Retreatment | 1 | 2014 | 104 | 0.030 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2014 | 145 | 0.030 |
Why?
|
| Phenotype | 1 | 2021 | 2545 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2014 | 136 | 0.030 |
Why?
|
| Protein Binding | 1 | 2018 | 1526 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2019 | 1385 | 0.020 |
Why?
|
| Cause of Death | 1 | 2014 | 271 | 0.020 |
Why?
|
| Mortality | 1 | 2014 | 156 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2014 | 774 | 0.020 |
Why?
|
| Mutation | 1 | 2024 | 4265 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 2787 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2014 | 210 | 0.020 |
Why?
|
| Embryonic Stem Cells | 1 | 2013 | 85 | 0.020 |
Why?
|
| Kallikreins | 1 | 2012 | 46 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2012 | 181 | 0.020 |
Why?
|
| United States Department of Defense | 1 | 2011 | 4 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2014 | 727 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 888 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2012 | 161 | 0.020 |
Why?
|
| Health Status | 1 | 2014 | 373 | 0.020 |
Why?
|
| Contrast Media | 1 | 2016 | 986 | 0.020 |
Why?
|
| Universities | 1 | 2011 | 150 | 0.020 |
Why?
|
| Diarrhea | 1 | 2011 | 176 | 0.020 |
Why?
|
| Fatigue | 1 | 2011 | 181 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2014 | 806 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 1240 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2011 | 236 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2014 | 1004 | 0.020 |
Why?
|
| Smoking | 1 | 2014 | 647 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2012 | 381 | 0.020 |
Why?
|
| Mass Screening | 1 | 2014 | 706 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2013 | 700 | 0.020 |
Why?
|
| Patient Selection | 1 | 2012 | 688 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 916 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 1849 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2008 | 121 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2012 | 557 | 0.020 |
Why?
|
| Cell Death | 1 | 2008 | 252 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 6922 | 0.020 |
Why?
|
| Cell Division | 1 | 2008 | 689 | 0.020 |
Why?
|
| Adolescent | 1 | 2019 | 9550 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2008 | 515 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 1098 | 0.010 |
Why?
|
| Homeostasis | 1 | 2008 | 459 | 0.010 |
Why?
|
| Chorionic Gonadotropin | 1 | 2001 | 69 | 0.010 |
Why?
|
| Thyroid Function Tests | 1 | 2001 | 123 | 0.010 |
Why?
|
| Pedigree | 1 | 2001 | 962 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2001 | 679 | 0.010 |
Why?
|
| Thyroid Hormones | 1 | 2001 | 350 | 0.010 |
Why?
|
| Pregnancy | 1 | 2001 | 3128 | 0.010 |
Why?
|